Oxigene: OXGN - A Tremendous Biotech Opportunity

I recently heard a technical presentation from a professor doing research with some of the compounds being developed by the biotech company Oxigene. He discussed the outstanding clinical results the compounds are showing in treating cancer as well as macular degeneration. The compounds work by closing up existing blood vessels in tumors, and can also be applied to help fight macular degeneration of the retina. The clinical trials are doing well, a large pipeline exists, and the process of obtaining FDA approval looks on target. That information alone intrigued me, but would not be enough to make me interested in investing. But he also discussed the management of the company, noting how the top leaders have proven backgrounds of bringing drugs to market with other leading companies. That kind of experience is vital. That kind of expertise is needed to give a company a healthy chance. After looking further into Oxigene, I've decided that they indeed have a powerful pipeline with large growth potential and the opportunity to bring these successfully to market. I'm in. I bought some in late November around $4 a share. It's now at $5, and I'm planning to add more because I think this can increase many times in value in the next few years. My recommendation: buy Oxigene under $6 and don't sell for less than $10. But keep some until it goes much higher.

links: digg this    del.icio.us    technorati    reddit